Vega Therapeutics Inc.

von Willebrand Disease

Research activity is concentrated on von Willebrand Disease, with clinical interest in preventing bleeding events in adolescent and adult patients. The sponsor’s work is centered on prophylactic treatment strategies for individuals who have not previously received von Willebrand Factor-containing concentrates on a routine preventive basis.

  • Bleeding event prevention
  • Prophylaxis in von Willebrand Disease
  • Subcutaneous therapy

The clinical program includes a multi-site research footprint across several countries, reflecting an interest in advancing treatment options for a rare bleeding disorder in both North America and international settings.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • A Study of VGA039 to Prevent Bleeding in Teenagers and Adults with von Willebrand Disease Who Have Not Used Regular Preventive Treatment Before

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Finland Germany Ireland Italy